perflutren has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Main, ML; Muskula, PR | 1 |
| Ahmad, M; Bhat, G; Hibberd, MG; Main, ML; Schmitz, S; Villanueva, F; Weiss, RJ | 1 |
1 review(s) available for perflutren and Cardiovascular Diseases
| Article | Year |
|---|---|
Safety With Echocardiographic Contrast Agents.
Topics: Albumins; Cardiovascular Diseases; Contrast Media; Drug Approval; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Echocardiography; Fluorocarbons; Humans; Patient Safety; Predictive Value of Tests; Risk Assessment; Risk Factors; United States; United States Food and Drug Administration | 2017 |
1 trial(s) available for perflutren and Cardiovascular Diseases
| Article | Year |
|---|---|
CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.
Topics: Cardiovascular Diseases; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Echocardiography; Female; Fluorocarbons; Humans; Male; Middle Aged; Prevalence; Registries; Risk Assessment; Risk Factors; United States | 2012 |